The effect of polyethylene glycol recombinant human growth hormone on growth and glucose metabolism in hypophysectomized rats

Zhang, Zhi Xin; Liu, Ying Ke; Pan, Hui; Lin, Pei; Zhang, Qiong; Zhao, Qiu Ling; Li, Hong; Cai, He

doi:10.1016/j.ghir.2011.12.002

Cited by 5 publications

(3 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence from animal models shows that hypophysectomy in rats significantly decreased body weight, tail length, and bone lengths, as well as bone mineral density. These results improved to normal levels with the treatment of growth hormone through daily injections of 0.25 mg/kg of rhGH [32]. However, hypophysectomy also renders the animals deficient in other growth-regulating hormone systems.…”

Section: Animal Models For Studying the Effect Of Longitudinal Bone G...mentioning

confidence: 96%

The Effects of Natural Product-Derived Extracts for Longitudinal Bone Growth: An Overview of In Vivo Experiments

Lim,

Lee

2023

IJMS

View full text Add to dashboard Cite

Approximately 80% of children with short stature are classified as having Idiopathic Short Stature (ISS). While growth hormone (GH) treatment received FDA approval in the United States in 2003, its long-term impact on final height remains debated. Other treatments, like aromatase inhibitors, metformin, and insulin-like growth factor-1 (IGF-1), have been explored, but there is no established standard treatment for ISS. In South Korea and other Asian countries, East Asian Traditional Medicine (EATM) is sometimes employed by parents to potentially enhance their children’s height growth, often involving herbal medicines. One such product, Astragalus membranaceus extract mixture HT042, claims to promote height growth in children and has gained approval from the Korean Food and Drug Administration (KFDA). Research suggests that HT042 supplementation can increase height growth in children without skeletal maturation, possibly by elevating serum IGF-1 and IGF-binding protein-3 levels. Preclinical studies also indicate the potential benefits of natural products, including of EATM therapies for ISS. The purpose of this review is to offer an overview of bone growth factors related to ISS and to investigate the potential of natural products, including herbal preparations, as alternative treatments for managing ISS symptoms, based on their known efficacy in in vivo studies.

show abstract

Section: Animal Models For Studying the Effect Of Longitudinal Bone G...mentioning

confidence: 96%

The Effects of Natural Product-Derived Extracts for Longitudinal Bone Growth: An Overview of In Vivo Experiments

Lim,

Lee

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…A PEG-rhGH dose of 0.14 mg/kg/week is equivalent to a daily rhGH dose of 0.12 IU/kg/d, which is within the recommended dose range for children with GHD. In addition, results of an animal study reported that in rats, a single PEG-rhGH dose of 0.14 mg/kg/week showed the same expected linear growth as a daily rhGH dose of 0.25 mg/kg/week ( Zhang et al, 2012 ). Taken together, the present study aimed to compare the efficacy and safety of PEG-rhGH treatment at a dose of 0.14 mg/kg/week to 0.2 mg/kg/week in children with GHD.…”

Section: Introductionmentioning

confidence: 99%

Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study

et al. 2022

View full text Add to dashboard Cite

Objective: Polyethylene glycol recombinant human growth hormone (PEG-rhGH, Jintrolong®) is the first long-acting rhGH preparation that is approved to treat children with growth hormone deficiency (GHD) in China. Clinical experience with dose selections of PEG-rhGH is scarce. The present study compared the efficacy and safety of a lower dose to increase dosing regimens of PEG-rhGH treatment.Methods: A multicenter, randomized, open-label, dose-comparison clinical study was conducted to compare the improvements in the height standard deviation score (Ht SDS), height velocity (HV), insulin-like growth factor-1 (IGF-1) SDS, and safety profiles of children with GHD who are treated with 0.2 mg/kg/week of PEG-rhGH dose or 0.14 mg/kg/week for 26 weeks.Results: Ht SDS, HV, and IGF-1 SDS increased significantly after PEG-rhGH treatment in the two dose groups (p < 0.05). The improvements of Ht SDS, HV, and IGF-1 SDS were more significant in the high-dose group than in the low-dose group (p < 0.05). Ht SDS improvement in low-dose group was not non-inferiority to that in the high-dose group (p = 0.2987). The incidences of adverse events were comparable between the two groups.Conclusion: The improvements of Ht SDS, HV, and IGF-1 SDS were more significant in the high-dose group than in the low-dose group (p < 0.05). PEG-rhGH at the dose of 0.14 mg/kg/week was effective and safe for children with GHD.Clinical Trial Registration:clinicaltrials.gov, identifier NCT02908958.

show abstract

“…Surgical hypophysectomy has long been the standard for inducing pituitary hormone deficiencies in animal models and has primarily been performed on immature pigs, rats and mice for short term monitoring regimens. Using a temporal surgical approach, animals could not eat after surgery, probably due to jaw-muscle and jaw-joint pain (Amet et al., 2010; Kwak et al., 2009; Link and St Clair, 1954; Zhang et al., 2012).…”

Section: Introductionmentioning

confidence: 99%

Towards a Göttingen minipig model of adult onset growth hormone deficiency: evaluation of stereotactic electrocoagulation method

Ørstrup

Tvilling

Orłowski

et al. 2019

Heliyon

View full text Add to dashboard Cite

BackgroundAdult onset growth hormone (GH) deficiency (AGDH) is a potentially underdiagnosed condition, caused by damage to the pituitary gland. AGHD is treated with growth hormone replacement therapy. A large variety of clinical symptoms and changes in the metabolic homeostasis can be observed and quantified. New large animal models are needed for future drug development.New methodIn this study, we evaluate methods for a new large non-primate animal model of GH deficiency in post pubertal Göttingen Minipigs (minipig). Lesions in the pituitary gland were made by stereotaxic monopolar thermo-coagulation guided by magnetic resonance imaging (MRI), and pituitary function was evaluated using insulin tolerance test (ITT) with measurements of growth hormone secretion induced by hypoglycemia.ResultsLesions were successfully applied to the pituitary gland without any damage to surrounding tissue including the hypothalamus, which was confirmed by post-operative MRI and post mortem histology. Plasma levels of GH during ITT showed no decrease in secreted levels one week after surgery compared to levels obtained before surgery.Comparison with existing methodsCompared to other GH insufficiency models, eloquent brain tissue is spared. Furthermore, alternatively to rodent models, a large animal model would allow the use of human intended equipment to evaluate disease. Using the minipig avoids social, economical and ethical issues, compared with primates.ConclusionThe lesions did not remove all GH production, but proof of concept is demonstrated. In addition, the ITT is presented as a safe and efficient method to diagnose GH deficiency in minipigs.

show abstract

The effect of polyethylene glycol recombinant human growth hormone on growth and glucose metabolism in hypophysectomized rats

Cited by 5 publications

References 45 publications

The Effects of Natural Product-Derived Extracts for Longitudinal Bone Growth: An Overview of In Vivo Experiments

The Effects of Natural Product-Derived Extracts for Longitudinal Bone Growth: An Overview of In Vivo Experiments

Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study

Towards a Göttingen minipig model of adult onset growth hormone deficiency: evaluation of stereotactic electrocoagulation method

Contact Info

Product

Resources

About